{"id":906174,"date":"2025-11-05T17:37:13","date_gmt":"2025-11-05T22:37:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/"},"modified":"2025-11-05T17:37:13","modified_gmt":"2025-11-05T22:37:13","slug":"mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/","title":{"rendered":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Nov.  05, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j6TbCON6u-ozU942LgBPgiMwXC9BWPCWxax_unbT5gDimzowtQMC2A5qpaieepbhZ9CQvC7IUifGaj50vbTYUcXQPzgYQE4d3NzKeBAKGkQ=\" rel=\"nofollow\" target=\"_blank\">MiNK Therapeutics<\/a>, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th.<\/p>\n<p align=\"left\">The announcement follows MiNK\u2019s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company\u2019s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors.<\/p>\n<p align=\"left\">MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, and upcoming corporate milestones.<\/p>\n<p align=\"left\">\n        <strong>Conference Participant Dial Information<\/strong><br \/>\n        <br \/>United States &#8211; New York (646) 307-1963<br \/>USA &amp; Canada &#8211; Toll-Free (800) 715-9871<br \/>Conference ID: 3474114<\/p>\n<p align=\"left\">\n        <strong>Webcast &amp; Replay Information<\/strong><br \/>\n        <br \/>A live webcast and replay of the conference call will be accessible from the Events &amp; Presentations page of the Company\u2019s website following the event.<\/p>\n<p align=\"left\">Live event link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HFDWYdaSTJoWHKYaKo68NYFDw3LChS31Ix2H1WHhQkdjjtQcltfb1cWbzBfk9mC8j90p2p9UZ0Qfiq-_5iOU4mIodsrb3y0TLNbeO_guc0XzhIx_E4oZY4zv93LO94wruNNrPNr1hkjG9VStuAphT9_-8fZYyzTObkPKbG71-sc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/4bufw45x<\/a><br \/>Webcast Replay: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HFDWYdaSTJoWHKYaKo68NcrckZdAittVkphYcLNa6QXNtcaY9ggNrMRffHeqWYewAwHCO0NpcvlJSZ7qm9nb4YUvmX8RSo_FbGgS0nTMH6DW08OjFiDkS3oyLPW_fJsMTlIE2bHjF-gMa-wMtSD-DEYKaAlvJtadS8_xkKba2fLCDe603sGwm_Iae3MHkCLZqD52KS2rwmTvMRsb4d8kbg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/investor.minktherapeutics.com\/events-and-presentations<\/a><\/p>\n<p align=\"left\">\n        <strong>About MiNK Therapeutics<\/strong>\n      <\/p>\n<p align=\"left\">MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK\u2019s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.<\/p>\n<p align=\"left\">Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK\u2019s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under \u201cRisk Factors\u201d in MiNK\u2019s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.<\/p>\n<p align=\"left\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<p align=\"left\">Investor Contact: 917-362-1370 | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nlGDl-lzcwx76bFxCV37RfiwHPMLcolcOGFbfP25oxG7a2WNMXWJ-T3qjPi30zErPr1_KGsCZfMxdS7GDVGyDx3FbXVwtK9oWoUoLG-378tFtU-0_vTJ1sb-e7pR2_R7\" rel=\"nofollow\" target=\"_blank\">investor@minktherapeutics.com<\/a><br \/>Media Contact: 781-674-4428 | <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a34CzamqmOOXpeujR_Cb-1rJixo6RifJjkDTXi8XyV3YuOH03cXbv2YmwsuvehEQlK0m32GEVPoNPuD_8dwluo9parcMQOO_HJZM6gDJgqXVXjPKK6Sf92enHA9TivtMh3QAFl1wfyb0M4odyAJakw==\" rel=\"nofollow\" target=\"_blank\">communications@minktherapeutics.com<\/a><\/p>\n<p align=\"left\">Source: MiNK Therapeutics<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmE3YTk4OWUtMjJiZi00NDUxLThlMTItZDk2NmMxZTQyZjFlLTEyMzQ3NjQtMjAyNS0xMS0wNS1lbg==\/tiny\/MiNK-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK\u2019s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company\u2019s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-906174","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK\u2019s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company\u2019s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, &hellip; Continue reading &quot;MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T22:37:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development\",\"datePublished\":\"2025-11-05T22:37:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/\"},\"wordCount\":414,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/\",\"name\":\"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=\",\"datePublished\":\"2025-11-05T22:37:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/","og_locale":"en_US","og_type":"article","og_title":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development - Market Newsdesk","og_description":"NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) &#8212; MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK\u2019s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company\u2019s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, &hellip; Continue reading \"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-05T22:37:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development","datePublished":"2025-11-05T22:37:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/"},"wordCount":414,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/","name":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=","datePublished":"2025-11-05T22:37:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2OTM4NyM3MjQ2MDU5IzIyMjMyMTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-third-quarter-2025-financial-results-and-highlight-clinical-and-corporate-milestones-advancing-inkt-platform-toward-pivotal-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/906174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=906174"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/906174\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=906174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=906174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=906174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}